446 related articles for article (PubMed ID: 32295913)
1. Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
Maxwell JW; Falcinelli SD; Nefedov A; Dorfmeier C; Wu G; Dewey M; Webber AL; Archin NM; Margolis DM; Hazuda DJ; Barnard RJO; Howell BJ
J Virol; 2020 Jun; 94(13):. PubMed ID: 32295913
[TBL] [Abstract][Full Text] [Related]
2. Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency.
Archin NM; Kirchherr JL; Sung JA; Clutton G; Sholtis K; Xu Y; Allard B; Stuelke E; Kashuba AD; Kuruc JD; Eron J; Gay CL; Goonetilleke N; Margolis DM
J Clin Invest; 2017 Aug; 127(8):3126-3135. PubMed ID: 28714868
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors induce complex host responses that contribute to differential potencies of these compounds in HIV reactivation.
Beliakova-Bethell N; Mukim A; White CH; Deshmukh S; Abewe H; Richman DD; Spina CA
J Biol Chem; 2019 Apr; 294(14):5576-5589. PubMed ID: 30745362
[TBL] [Abstract][Full Text] [Related]
4. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat.
Archin NM; Bateson R; Tripathy MK; Crooks AM; Yang KH; Dahl NP; Kearney MF; Anderson EM; Coffin JM; Strain MC; Richman DD; Robertson KR; Kashuba AD; Bosch RJ; Hazuda DJ; Kuruc JD; Eron JJ; Margolis DM
J Infect Dis; 2014 Sep; 210(5):728-35. PubMed ID: 24620025
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.
Wei DG; Chiang V; Fyne E; Balakrishnan M; Barnes T; Graupe M; Hesselgesser J; Irrinki A; Murry JP; Stepan G; Stray KM; Tsai A; Yu H; Spindler J; Kearney M; Spina CA; McMahon D; Lalezari J; Sloan D; Mellors J; Geleziunas R; Cihlar T
PLoS Pathog; 2014 Apr; 10(4):e1004071. PubMed ID: 24722454
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional Modulation of Human Endogenous Retroviruses in Primary CD4+ T Cells Following Vorinostat Treatment.
White CH; Beliakova-Bethell N; Lada SM; Breen MS; Hurst TP; Spina CA; Richman DD; Frater J; Magiorkinis G; Woelk CH
Front Immunol; 2018; 9():603. PubMed ID: 29706951
[TBL] [Abstract][Full Text] [Related]
8. Dose-responsive gene expression in suberoylanilide hydroxamic acid-treated resting CD4+ T cells.
Reardon B; Beliakova-Bethell N; Spina CA; Singhania A; Margolis DM; Richman DR; Woelk CH
AIDS; 2015 Nov; 29(17):2235-44. PubMed ID: 26258524
[TBL] [Abstract][Full Text] [Related]
9. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
Archin NM; Liberty AL; Kashuba AD; Choudhary SK; Kuruc JD; Crooks AM; Parker DC; Anderson EM; Kearney MF; Strain MC; Richman DD; Hudgens MG; Bosch RJ; Coffin JM; Eron JJ; Hazuda DJ; Margolis DM
Nature; 2012 Jul; 487(7408):482-5. PubMed ID: 22837004
[TBL] [Abstract][Full Text] [Related]
10. The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events.
Lucera MB; Tilton CA; Mao H; Dobrowolski C; Tabler CO; Haqqani AA; Karn J; Tilton JC
J Virol; 2014 Sep; 88(18):10803-12. PubMed ID: 25008921
[TBL] [Abstract][Full Text] [Related]
11. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
[TBL] [Abstract][Full Text] [Related]
12. Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb.
Jamaluddin MS; Hu PW; Jan Y; Siwak EB; Rice AP
AIDS Res Hum Retroviruses; 2016 Feb; 32(2):169-73. PubMed ID: 26727990
[TBL] [Abstract][Full Text] [Related]
13. Integrated Assessment of Viral Transcription, Antigen Presentation, and CD8
Mota TM; McCann CD; Danesh A; Huang SH; Magat DB; Ren Y; Leyre L; Bui TD; Rohwetter TM; Kovacs CM; Benko E; MacLaren L; Wimpelberg A; Cannon CM; Hardy WD; Safrit JT; Jones RB
J Virol; 2020 Apr; 94(9):. PubMed ID: 32051267
[TBL] [Abstract][Full Text] [Related]
14. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
Elliott JH; Wightman F; Solomon A; Ghneim K; Ahlers J; Cameron MJ; Smith MZ; Spelman T; McMahon J; Velayudham P; Brown G; Roney J; Watson J; Prince MH; Hoy JF; Chomont N; Fromentin R; Procopio FA; Zeidan J; Palmer S; Odevall L; Johnstone RW; Martin BP; Sinclair E; Deeks SG; Hazuda DJ; Cameron PU; Sékaly RP; Lewin SR
PLoS Pathog; 2014 Oct; 10(10):e1004473. PubMed ID: 25393648
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic reactivation of latent feline immunodeficiency virus ex vivo in peripheral CD4+ T-lymphocytes.
McDonnel SJ; Sparger EE; Luciw PA; Murphy BG
Virus Res; 2012 Dec; 170(1-2):174-9. PubMed ID: 23073179
[TBL] [Abstract][Full Text] [Related]
16. H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells.
Tripathy MK; McManamy ME; Burch BD; Archin NM; Margolis DM
J Virol; 2015 Aug; 89(16):8392-405. PubMed ID: 26041287
[TBL] [Abstract][Full Text] [Related]
17. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.
Banga R; Procopio FA; Cavassini M; Perreau M
J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693
[TBL] [Abstract][Full Text] [Related]
18. The Effects of Human Immunodeficiency Virus Type 1 (HIV-1) Antigen-Expanded Specific T-Cell Therapy and Vorinostat on Persistent HIV-1 Infection in People With HIV on Antiretroviral Therapy.
Gay CL; Hanley PJ; Falcinelli SD; Kuruc JD; Pedersen SM; Kirchherr J; Raines SLM; Motta CM; Lazarski C; Chansky P; Tanna J; Shibli A; Datar A; McCann CD; Sili U; Ke R; Eron JJ; Archin N; Goonetilleke N; Bollard CM; Margolis DM
J Infect Dis; 2024 Mar; 229(3):743-752. PubMed ID: 38349333
[TBL] [Abstract][Full Text] [Related]
19. The thioacetate-ω(γ-lactam carboxamide) HDAC inhibitor ST7612AA1 as HIV-1 latency reactivation agent.
Badia R; Grau J; Riveira-Muñoz E; Ballana E; Giannini G; Esté JA
Antiviral Res; 2015 Nov; 123():62-9. PubMed ID: 26348004
[TBL] [Abstract][Full Text] [Related]
20. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A
J Virol; 2018 May; 92(10):. PubMed ID: 29343578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
